Compound rhizoma bletillae polysaccharide liposome gel, preparation method and scar-free healing application
By preparing a curcumin-loaded compound Bletilla striata polysaccharide liposome gel and combining it with Artemisia selengensis oil and Bletilla striata polysaccharide, the problems of low water solubility and poor stability of curcumin in wound healing were solved, achieving scar-free and rapid healing of the wound.
Patent Information
- Application Number
- CN202510955289.0
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2025-07-11
- Publication Date
- 2025-10-03
AI Technical Summary
Existing technologies make it difficult to effectively prevent scar formation while promoting wound healing. Curcumin has problems such as low water solubility, short half-life, and poor stability in clinical applications. Traditional excipient selection fails to fully utilize the synergistic effect of the drug and the carrier.
Compound Bletilla striata polysaccharide liposome gel was used to prepare curcumin-loaded nanostructured liposome gel by combining curcumin with Artemisia selengensis oil and Bletilla striata polysaccharide. The emulsifying effect of Bletilla striata polysaccharide and the gel formation of Carbomer 940 were utilized to achieve sustained release of the drug and promote scarless wound healing.
It improves the repair effect of curcumin on the wound surface, promotes scar-free healing of the wound surface, has good biocompatibility and sustained-release effect, significantly improves the wound healing rate and inhibits scar formation.
Smart Images

Figure BDA0005494139830000101 
Figure BDA0005494139830000111 
Figure BDA0005494139830000112
Abstract
Description
Technical Field
[0001] The present invention relates to the technical field of pharmaceutical preparations, and in particular to a compound bletilla striata polysaccharide liposome gel, a preparation method and scar-free healing application. Background Art
[0002] Pathological scarring during skin wound healing is a significant clinical challenge in wound repair. Statistically, hypertrophic scars and keloids are highly prevalent in patients with trauma, burns, and other conditions. These scars not only lead to functional impairments such as limited joint mobility and skin contractures, but also increase the psychological burden on patients. However, existing treatments struggle to achieve the dual goals of promoting healing and combating scarring.
[0003] Curcumin, a yellow pigment extracted from the rhizomes of turmeric (Zingiber officinale), is an acidic polyphenol widely used in medicine and food. Modern research has shown that curcumin exhibits antibacterial, anti-inflammatory, antioxidant, anticoagulant, and anti-tumor effects. However, its clinical application is significantly limited by its low solubility in water, short half-life, and poor stability.
[0004] Nanostructured lipid carriers (NLCs) are improved carriers of solid lipid nanoparticles. They replace part of the solid lipids with liquid lipids to form mixed lipids and keep them solid at room temperature and body temperature, with a particle size of less than 500nm. Nanostructured lipid carriers have good biocompatibility and stability, and have a high load and less leakage of embedded materials. Studies have found that nanostructured lipid carriers can significantly improve the solubility and bioavailability of curcumin, thereby improving its pharmaceutical activity. For example, the Chinese invention patent application with publication number CN116139026A, "A fatty acid nanostructured lipid carrier for improving the bioaccessibility of curcumin", discloses a nanostructured lipid carrier for preparing curcumin with conjugated linoleic acid as liquid lipid and stearic acid as solid lipid, which improves the bioacceptability of curcumin and the antioxidant property of the system. At present, the commonly used liquid lipids for constructing NLC include olive oil, coconut oil, pumpkin seed oil, etc., and the commonly used emulsifiers include lecithin, poloxamer, etc. However, the selection of traditional excipients mostly focuses on carrier molding and drug encapsulation, ignoring the efficacy superposition between excipients and drugs, resulting in insufficient exploration of therapeutic potential.
[0005] In order to further enhance the wound healing effect of curcumin, the present invention innovatively applies the formulation design concept of "drug-excipient integration", breaking through the limitation of traditional excipients that only bear the function of drug carrying, and realizing the synergistic enhancement of drug delivery and pharmacological effects by selecting carrier materials with therapeutic activity. In this invention, Ai Na sesame oil is used as liquid lipid to replace part of monostearate glycerol, combined with Bletilla striata polysaccharide as an emulsifier and component of the gel, to prepare a compound Bletilla striata polysaccharide nanostructured lipid carrier gel loaded with curcumin, aiming to provide a new drug option for clinical use that can promote scar-free wound healing. Summary of the Invention
[0006] The purpose of the present invention is to provide a compound Bletilla striata polysaccharide liposome gel and a preparation method thereof.
[0007] Another object of the present invention is to provide the use of the above-mentioned compound Bletilla striata polysaccharide liposome gel in the preparation of a medicine for promoting scarless wound healing.
[0008] To achieve the above purpose, the technical solutions adopted by the present invention are as follows:
[0009] The compound Bletilla striata polysaccharide liposome gel of the present invention is obtained by uniformly mixing a gel matrix and nanostructured liposomes loaded with curcumin;
[0010] The gel matrix comprises the following components in percentage by mass: 1% to 11% of Bletilla striata polysaccharide, 0.3% to 1.3% of Carbomer 940, 1% to 7% of glycerol, and the solvent is water;
[0011] The curcumin-loaded nanostructured liposomes comprise the following components in percentage by mass: an oil phase consisting of 0.5% glyceryl monostearate and 1% linalool oil; an aqueous phase consisting of 4% egg yolk lecithin, 1% co-emulsifier consisting of poloxamer 188 and bletilla striata polysaccharide, and distilled water; and curcumin at a concentration of 0.5 to 3 mg / mL in the nanostructured liposomes; wherein the mass ratio of poloxamer 188 to bletilla striata polysaccharide is 1:2.
[0012] The volume ratio of the gel matrix to the curcumin-loaded nanostructured liposome is 0.5-2:1.
[0013] Preferably, in the compound Bletilla striata polysaccharide liposome gel of the present invention, the gel matrix comprises the following components in percentage by mass: 5% to 9% of Bletilla striata polysaccharide, 0.9% to 1.3% of Carbomer 940, 3% to 5% of glycerol, and the solvent is water.
[0014] Further preferably, in the compound Bletilla striata polysaccharide liposome gel of the present invention, the gel matrix comprises the following components in percentage by mass: 7% Bletilla striata polysaccharide, 1.0% Carbomer 940, 4% glycerol, and the solvent is water.
[0015] Preferably, in the compound Bletilla striata polysaccharide liposome gel of the present invention, the concentration of curcumin in the nanostructured liposomes loaded with curcumin is 2 mg / mL.
[0016] Preferably, in the compound Bletilla striata polysaccharide liposome gel of the present invention, the volume ratio of the gel matrix to the curcumin-loaded nanostructured liposomes is 1 to 2:1.
[0017] Further preferably, in the compound Bletilla striata polysaccharide liposome gel of the present invention, the volume ratio of the gel matrix to the curcumin-loaded nanostructured liposomes is 1:1.
[0018] The preparation method of the compound Bletilla striata polysaccharide liposome gel of the present invention comprises the following steps:
[0019] S1 Preparation of curcumin-loaded nanostructured liposomes:
[0020] The preparation method is a heating melting-ultrasonic dispersion method, wherein curcumin is added to the oil phase, and the aqueous phase is slowly injected into the oil phase under magnetic stirring, continuously stirred, ultrasonically treated with a probe-type ultrasonic processor, cooled, and filtered to obtain the product;
[0021] S2 Preparation of gel matrix:
[0022] Take Carbomer 940 and soak it in distilled water to make it swell, add Bletilla striata polysaccharide solution, stir in a water bath, add glycerol, mix well, and adjust the pH value to 6.5-7 with triethylamine to obtain the product;
[0023] S3 Preparation of compound Bletilla striata polysaccharide liposome gel:
[0024] The curcumin-loaded nanostructured liposomes prepared in step S1 and the gel matrix prepared in step S2 are mixed evenly in proportion to obtain the product.
[0025] Preferably, in the preparation method of the compound Bletilla striata polysaccharide liposome gel of the present invention, in step S1: the temperature of the magnetic stirring is 65°C; the time of the continuous stirring is 25 minutes; the ultrasonic power of the probe-type ultrasonic processor is 450W, and the ultrasonic time is 15 minutes; the cooling time is 5 minutes; and the filtration is specifically through a 0.22μm microporous filter membrane, and the number of filtrations is 3 times.
[0026] Preferably, in the method for preparing the compound Bletilla striata polysaccharide liposome gel of the present invention, the stirring in a water bath in step S2 is specifically: stirring in a 60° C. water bath for 6 hours.
[0027] The invention discloses an application of the compound Bletilla striata polysaccharide liposome gel in the preparation of a medicine for promoting scar-free wound healing.
[0028] Beneficial effects of the present invention:
[0029] 1. The present invention provides a compound Bletilla striata polysaccharide liposome gel prepared by mixing a gel matrix and curcumin-loaded nanostructured liposomes. The preparation method is simple and easy. By combining curcumin with Artemisia selengensis oil and Bletilla striata polysaccharide to prepare a compound gel preparation, the wound repair effect of curcumin is greatly enhanced, and scar-free wound healing can be promoted, thereby having great clinical application value.
[0030] 2. The present invention determined through a single factor investigation experiment that the optimal ratio of nanostructured liposomes loaded with curcumin is: the ratio of poloxamer 188 to Bletilla striata polysaccharide is 1:2, the proportion of Artemisia selengensis oil is 1%, the proportion of egg yolk lecithin is 4%, the proportion of curcumin in Bletilla striata polysaccharide liposome gel is 2 mg / mL, and the proportion of glyceryl monostearate is 0.5%. The average particle size of the nanostructured lipids in the nanostructured liposomes loaded with curcumin prepared under the above optimal ratio is (172.6±1.0) nm, PDI is 0.106±0.037, EE (%) is 89.52±2.28%, and LE (%) is 4.73±0.08%.
[0031] 3. The present invention determined through single factor investigation experiments that the optimal ratio of the gel matrix is: 1% of Carbomer 940, 4% of glycerol, and 7% of Bletilla striata polysaccharide.
[0032] 4. The present invention examines the comprehensive scores of the compound Bletilla striata polysaccharide liposome gel prepared under different ratios of gel matrix and curcumin-loaded nanostructured liposome, and determines that the optimal volume ratio of the two is 1:1.
[0033] 5. Through in vitro release experiments, it was found that the release curve of free curcumin showed that its release rate was fast, with a burst release, and the release rate within 264 hours reached 67.92%; while the release rates of the curcumin-loaded nanostructured liposomes and the compound Bletilla striata polysaccharide liposome gel were slower than that of free curcumin, with release rates of 35.52% and 30.12% within 264 hours, respectively, and the sustained release could reach 264 hours, indicating that the compound Bletilla striata polysaccharide liposome gel provided by the present invention has a stronger sustained-release effect than free curcumin.
[0034] 6. Through biosafety assessment and cell scratch test, it was found that the CUR@BBO-BSPNLCG provided by the present invention has good blood compatibility and cell compatibility, and can significantly promote the migration of L929 cells, confirming that the compound Bletilla striata polysaccharide liposome gel provided by the present invention has good biosafety and the ability to promote wound healing.
[0035] 7. Through the study of wound healing and scar prevention in vivo, it was found that compared with other groups, the CUR@BBO-BSPNLCG group showed the fastest wound healing rate, and no scar tissue was formed after healing. Its therapeutic effect was significantly better than that of the positive drug excipient group. Histological evaluation and immunohistochemical analysis confirmed that the compound Bletilla striata polysaccharide liposome gel provided by the present invention showed synergistic therapeutic advantages in vascular remodeling, inflammation regulation and TGF-β1 expression inhibition. The above proves that the compound Bletilla striata polysaccharide liposome gel provided by the present invention can effectively promote scar-free healing of wounds and has great promotion and application value. BRIEF DESCRIPTION OF THE DRAWINGS
[0036] Figure 1 The average particle size and particle size distribution of BBO-BSP NLC samples prepared at different proportions of Artemisia selengensis oil;
[0037] Figure 2 The average particle size and particle size distribution of BBO-BSP NLC samples prepared at different ratios of Poloxamer 188 and Bletilla striata polysaccharide;
[0038] Figure 3 The average particle size and particle size distribution of BBO-BSP NLC samples prepared at different egg yolk lecithin ratios;
[0039] Figure 4 is the standard curve of curcumin loading concentration and absorbance value;
[0040] Figure 5 is the comprehensive score of the gel matrix at different Bletilla striata polysaccharide ratios;
[0041] Figure 6 is the comprehensive score of the gel matrix at different Carbomer 940 ratios;
[0042] Figure 7 is the comprehensive score of the gel matrix at different glycerol ratios;
[0043] Figure 8 The comprehensive scores of CUR@BBO-BSP NLCGs prepared at different mixing ratios of gel matrix and CUR@BBO-BSP NLCs;
[0044] Figure 9 is the curcumin release curve;
[0045] Figure 10 It is the result of hemolysis rate determination;
[0046] Figure 11 The results of cell viability determination;
[0047] Figure 12 Representative images of L929 cell migration;
[0048] Figure 13 is the scratch closure rate;
[0049] Figure 14 Effects of CUR@BBO-BSP NLCG on scarless wound healing (Figure: A is a schematic diagram of the experimental design for scarless wound healing in rabbit ears; B is images of rabbit ear wounds in each treatment group at different time points; C is the time of scar formation in each group; D is the scar height in each group, n = 3);
[0050] Figure 15 The results of histological evaluation are shown in the figure (Figure A is the H&E, Masson's trichrome, and succinimidyl red staining of the wound 30 days after treatment; B is the scar elevation index (SEI) value of the wounds in different groups; C is the semi-quantitative analysis of collagen fiber density; D is the semi-quantitative analysis of succinimidyl red staining, n = 3);
[0051] Figure 16 The results of immunohistochemical analysis are shown in Figure 1 (A is the immunohistochemical staining of CD31, VEGF, TNF-α, IL-6 and TGF-β1; B is the semi-quantitative analysis of CD31; C is the semi-quantitative analysis of VEGF; D is the semi-quantitative analysis of TNF-α; E is the semi-quantitative analysis of IL-6; F is the semi-quantitative analysis of TGF-β1). DETAILED DESCRIPTION
[0052] The following is a detailed description of the technical solution of the present invention in conjunction with specific embodiments. The following embodiments are only for explanation and illustration, and do not constitute a limitation of the technical solution of the present invention.
[0053] Example 1
[0054] Compound Bletilla striata polysaccharide liposome gel is obtained by mixing a gel matrix and curcumin-loaded nanostructured liposomes. The specific composition is as follows:
[0055] The gel matrix comprises: 7% of Bletilla striata polysaccharide, 1.0% of Carbomer 940, 4% of glycerol, and the solvent is water.
[0056] The curcumin-loaded nanostructured liposomes include an oil phase consisting of 0.5% glyceryl monostearate and 1% linalool oil; an aqueous phase consisting of 4% egg yolk lecithin, 1% co-emulsifier consisting of poloxamer 188 and bletilla striata polysaccharide, and distilled water; 2 mg / mL of curcumin is contained in the oil phase; the mass ratio of poloxamer 188 to bletilla striata polysaccharide is 1:2;
[0057] The volume ratio of the gel matrix and curcumin-loaded nanostructured liposomes was 1:1.
[0058] Example 2
[0059] Compound Bletilla striata polysaccharide liposome gel is obtained by mixing a gel matrix and curcumin-loaded nanostructured liposomes. The specific composition is as follows:
[0060] The gel matrix comprises: 5% of Bletilla striata polysaccharide, 0.9% of Carbomer 940, 3% of glycerol, and the solvent is water.
[0061] The curcumin-loaded nanostructured liposomes include: an oil phase composed of 0.5% glyceryl monostearate and 1% linalool oil; an aqueous phase composed of 4% egg yolk lecithin, 1% co-emulsifier composed of poloxamer 188 and bletilla striata polysaccharide, and distilled water; 0.5 mg / mL of curcumin in the oil phase; wherein the mass ratio of poloxamer 188 to bletilla striata polysaccharide is 1:2;
[0062] The volume ratio of the gel matrix and curcumin-loaded nanostructured liposomes was 1:1.
[0063] Example 3
[0064] Compound Bletilla striata polysaccharide liposome gel is obtained by mixing a gel matrix and curcumin-loaded nanostructured liposomes. The specific composition is as follows:
[0065] The gel matrix comprises: 9% of Bletilla striata polysaccharide, 1.3% of Carbomer 940, 5% of glycerol, and the solvent is water.
[0066] The curcumin-loaded nanostructured liposomes include an oil phase consisting of 0.5% glyceryl monostearate and 1% linalool oil; an aqueous phase consisting of 4% egg yolk lecithin, 1% co-emulsifier consisting of poloxamer 188 and bletilla striata polysaccharide, and distilled water; 3 mg / mL of curcumin is contained in the oil phase; the mass ratio of poloxamer 188 to bletilla striata polysaccharide is 1:2;
[0067] The volume ratio of the gel matrix and curcumin-loaded nanostructured liposomes was 1:1.
[0068] Example 4
[0069] Compound Bletilla striata polysaccharide liposome gel is obtained by mixing a gel matrix and curcumin-loaded nanostructured liposomes. The specific composition is as follows:
[0070] The gel matrix comprises: 1% of Bletilla striata polysaccharide, 0.3% of Carbomer 940, 1% of glycerol, and the solvent is water.
[0071] The curcumin-loaded nanostructured liposomes include an oil phase consisting of 0.5% glyceryl monostearate and 1% linalool oil; an aqueous phase consisting of 4% egg yolk lecithin, 1% co-emulsifier consisting of poloxamer 188 and bletilla striata polysaccharide, and distilled water; 2 mg / mL of curcumin is contained in the oil phase; the mass ratio of poloxamer 188 to bletilla striata polysaccharide is 1:2;
[0072] The volume ratio of the gel matrix and curcumin-loaded nanostructured liposomes was 1:1.
[0073] Example 5
[0074] Compound Bletilla striata polysaccharide liposome gel is obtained by mixing a gel matrix and curcumin-loaded nanostructured liposomes. The specific composition is as follows:
[0075] The gel matrix comprises: 11% of Bletilla striata polysaccharide, 1.3% of Carbomer 940, 7% of glycerol, and the solvent is water.
[0076] The curcumin-loaded nanostructured liposomes include an oil phase consisting of 0.5% glyceryl monostearate and 1% linalool oil; an aqueous phase consisting of 4% egg yolk lecithin, 1% co-emulsifier consisting of poloxamer 188 and bletilla striata polysaccharide, and distilled water; 2 mg / mL of curcumin is contained in the oil phase; the mass ratio of poloxamer 188 to bletilla striata polysaccharide is 1:2;
[0077] The volume ratio of the gel matrix and curcumin-loaded nanostructured liposomes was 1:1.
[0078] Example 6
[0079] Compound Bletilla striata polysaccharide liposome gel is obtained by mixing a gel matrix and curcumin-loaded nanostructured liposomes. The specific composition is as follows:
[0080] The gel matrix comprises: 7% of Bletilla striata polysaccharide, 1.0% of Carbomer 940, 4% of glycerol, and the solvent is water.
[0081] The curcumin-loaded nanostructured liposomes include an oil phase consisting of 0.5% glyceryl monostearate and 1% linalool oil; an aqueous phase consisting of 4% egg yolk lecithin, 1% co-emulsifier consisting of poloxamer 188 and bletilla striata polysaccharide, and distilled water; 2 mg / mL of curcumin is contained in the oil phase; the mass ratio of poloxamer 188 to bletilla striata polysaccharide is 1:2;
[0082] The volume ratio of the gel matrix to the curcumin-loaded nanostructured liposomes was 0.5:1.
[0083] Example 7
[0084] Compound Bletilla striata polysaccharide liposome gel is obtained by mixing a gel matrix and curcumin-loaded nanostructured liposomes. The specific composition is as follows:
[0085] The gel matrix comprises: 7% of Bletilla striata polysaccharide, 1.0% of Carbomer 940, 4% of glycerol, and the solvent is water.
[0086] The curcumin-loaded nanostructured liposomes include an oil phase consisting of 0.5% glyceryl monostearate and 1% linalool oil; an aqueous phase consisting of 4% egg yolk lecithin, 1% co-emulsifier consisting of poloxamer 188 and bletilla striata polysaccharide, and distilled water; 2 mg / mL of curcumin is contained in the oil phase; the mass ratio of poloxamer 188 to bletilla striata polysaccharide is 1:2;
[0087] The volume ratio of the gel matrix and curcumin-loaded nanostructured liposomes was 2:1.
[0088] Example 8
[0089] The preparation method of compound Bletilla striata polysaccharide liposome gel comprises the following steps:
[0090] (1) Preparation of curcumin-loaded nanostructured liposomes:
[0091] The product was prepared by a heating melt-ultrasonic dispersion method. Curcumin was added to the oil phase, and the aqueous phase was slowly injected into the oil phase under magnetic stirring (65°C). The mixture was stirred continuously for 25 minutes, and ultrasonicated with a probe-type ultrasonic processor for 15 minutes (power of 450W). The mixture was cooled for 5 minutes and filtered through a 0.22μm microporous membrane for 3 times to obtain the product.
[0092] (2) Preparation of gel matrix:
[0093] Take Carbomer 940 and soak it in distilled water to make it swell, add Bletilla striata polysaccharide solution, stir in a 60℃ water bath for 6 hours, add glycerol, mix well, and adjust the pH value to 6.5-7 with triethylamine to obtain the product;
[0094] (3) Preparation of compound Bletilla striata polysaccharide liposome gel:
[0095] The curcumin-loaded nanostructured liposomes prepared in step S1 and the gel matrix prepared in step S2 are mixed evenly in proportion to obtain the product.
[0096] In order to further verify the reliability of the present invention and screen out the best solution, the inventors conducted a series of experiments, as follows:
[0097] 1. Experimental instruments and reagents
[0098] 1.1 Drugs and Reagents
[0099] Egg yolk lecithin, Beijing Solebao Technology Co., Ltd.; Poloxamer 188, Beijing Solebao Technology Co., Ltd.; Bletilla striata polysaccharide extract, Shaanxi Baichuan Biotechnology Co., Ltd.; Artemisia selengensis oil, Guizhou Miao Medicine Biotechnology Co., Ltd.; Glyceryl monostearate, Shanghai Maclean Biochemical Technology Co., Ltd.; Curcumin, Aladdin; Carbomer 940, Shanghai Maclean Biochemical Technology Co., Ltd.; Anhydrous ethanol, Chongqing Chuandong Chemical Group Co., Ltd.; Triethanolamine, Tianjin Fuyu Fine Chemical Co., Ltd.; Glycerol, Sinopharm Chemical Reagent Co., Ltd.; Methanol, Sinopharm Chemical Reagent Co., Ltd.
[0100] 1.2 Instruments
[0101] Thousandth electronic balance, Shanghai Benpu Instrument Co., Ltd.; ten-thousandth balance, Shanghai Sunny Hengping Scientific Instrument Co., Ltd.; DF-101S instant constant temperature heating magnetic stirrer, Shanghai Qiuzuo Scientific Instrument Co., Ltd.; ultrasonic cell disruptor, Ningbo Xinzhi Biotechnology Co., Ltd.; pipette, Dalong Medical Equipment Co., Ltd.; UC-5900 UV-visible spectrophotometer, Shanghai Yuanxi Co., Ltd.; DelsaMax PRO Beckman Nanoparticle Size Analyzer, Xiamen Lai Chi Electronic Technology Co., Ltd.; digital ultrasonic cleaning machine, Guangzhou Fanhua Technology Co., Ltd.
[0102] 2. Experimental methods
[0103] 2.1 Preparation of BBO-BSP NLC
[0104] 2.1.1 Preparation of BBO-BSP NLC
[0105] BBO-BSP NLC was prepared using a heat-melt-ultrasonic dispersion method. The oil phase consisted of glyceryl monostearate and blumeria balsamifera oil (BBO), while the aqueous phase consisted of distilled water, egg yolk lecithin (emulsifier), poloxamer 188, and Bletilla striata polysaccharide (BSP, co-emulsifier). The aqueous phase was slowly injected into the oil phase under magnetic stirring and stirred continuously for 25 minutes. Ultrasonication was then performed for 15 minutes using a probe-type ultrasonic processor at 70% power (450 W), followed by cooling for 5 minutes. Finally, the emulsion was filtered three times through a 0.22 μm microporous membrane.
[0106] 2.1.2 Single-factor investigation experiment for BBO-BSP NLC preparation
[0107] 2.1.2.1 Selection of liquid lipid ratio
[0108] The proportion of solid lipids was fixed at 0.5%, and the proportions of Artemisia selengensis oil were set at 0.5%, 1%, 2%, 3%, and 5%, respectively, to prepare BBO-BSP NLC. The optimal proportion of liquid lipids was selected based on the appearance, particle size, PDI, and stability of BBO-BSP NLC prepared with different Artemisia selengensis oil ratios.
[0109] 2.1.2.2 Selection of co-emulsifier ratio
[0110] The proportion of co-emulsifier was fixed at 1%, and the ratios of poloxamer 188 to Bletilla striata polysaccharide were set at 3:1, 2:1, 1:1, 1:2 and 1:3, respectively, to prepare BBO-BSP NLC. The optimal co-emulsifier ratio was selected based on the appearance, particle size, PDI and stability of BBO-BSP NLC prepared with different co-emulsifier ratios.
[0111] 2.1.2.3 Selection of emulsifier ratio
[0112] BBO-BSP NLC was prepared by setting the egg yolk lecithin ratio to 1%, 2%, 3%, 4%, and 5%, and the optimal egg yolk lecithin ratio was selected based on the appearance, particle size, PDI, and stability of BBO-BSP NLC prepared at different emulsifier ratios.
[0113] 2.2 Preparation of curcumin-loaded nanostructured lipids (CUR@BBO-BSP NLC)
[0114] 2.2.1 Preparation of CUR@BBO-BSP NLC
[0115] BBO-BSP NLC was prepared according to the above optimal formula. Curcumin was further added to the oil phase at concentrations of 0.5 mg / mL, 1 mg / mL, 2 mg / mL, and 3 mg / mL, respectively, to prepare CUR@BBO-BSP NLC. The final amount of curcumin added was determined based on the morphology of the obtained CUR@BBO-BSP NLC, the difficulty of passing through the microporous filter membrane, and the stability.
[0116] 2.2.2 Determination of encapsulation efficiency and drug loading
[0117] The Cur content in the prepared CUR@BBO-BSP NLC was determined by dialysis, and the Cur encapsulation efficiency EE (%) and drug loading LE (%) were calculated according to the following formulas:
[0118] EE(%)=(W Cur / W)×100%;
[0119] LE(%)=(W Cur / W1)×100%;
[0120] Among them, WCur is the encapsulated Cur content in Cur@BBO-BSP NLC; W is the total amount of Cur in Cur@BBO-BSP NLC; W1 is the total mass of Cur@BBO-BSP NLC.
[0121] 2.3 Preparation of gel matrix
[0122] 2.3.1 Preparation of gel matrix
[0123] The gel matrix is primarily composed of Bletilla striata polysaccharide, carbomer 940, and glycerin (humectant). The preparation method is as follows: An appropriate amount of carbomer 940 is added to distilled water to swell, followed by the addition of the Bletilla striata polysaccharide solution. After stirring in a 60°C water bath for 6 hours, an appropriate amount of glycerin is added and mixed thoroughly. Finally, triethylamine is added to adjust the pH to between 6.5 and 7.
[0124] 2.3.2 Single factor experiment for gel matrix preparation
[0125] Single-factor experiments were conducted to further optimize the gel matrix formulation, including Bletilla striata polysaccharide content (1%, 2%, 3%, 5%, 7%, 9%, and 11%), Carbomer 940 ratio (0.3%, 0.5%, 0.7%, 0.9%, 1.0%, 1.1%, and 1.3%), and glycerol concentration (1%, 2%, 3%, 4%, 5%, 6%, and 7%). The resulting gels should have a uniform, smooth appearance and maintain a gel-like consistency at room temperature without drying or liquefying. A comprehensive scoring method was used to optimize these parameters: comprehensive score = appearance score × 0.2 + spreadability score × 0.3 + uniformity score × 0.2 + viscosity score × 0.3. The comprehensive scoring criteria are shown in Table 1.
[0126] Table 1 Comprehensive scoring criteria
[0127]
[0128] 2.4 Preparation of CUR@BBO-BSP NLCG
[0129] After the gel matrix formula was determined according to the comprehensive scoring method, it was mixed with CUR@BBO-BSP NLC at ratios of 1:1, 1:2, and 2:1 to prepare CUR@BBO-BSP NLCG, and the comprehensive scoring method was used to score them to determine the mixing ratio.
[0130] 2.5 In vitro release experiment
[0131] Preparation of the Cur reference solution: Dissolve an appropriate amount of curcumin in 60% ethanol and continue adding 60% ethanol to a desired concentration to obtain the Cur reference solution. Next, 1 mL each of the Cur reference solution, Cur@BBO-BSP NLC, and CUR@BBO-BSP NLCG (all containing 1 mg / mL of curcumin) was placed into dialysis bags (molecular cutoff: 3500 Da). The bags were tied at both ends and placed in a centrifuge tube containing 30 mL of release medium (PBS buffer containing 2% Tween-80, pH 7.35). The bags were shaken at 37°C and 150 rpm. 1 mL of sample was withdrawn from each of the three release media at 0, 15, 30 min, and 1, 2, 4, 6, 8, 12, 16, 20, 25, 36, 48, 72, 96, 120, 168, 216, and 264 h. After each sampling, an equal volume of fresh release medium was added promptly. The Cur content was calculated by UV-visible spectrophotometry at a wavelength of 424 nm using the standard curve method. The cumulative release amount and cumulative release rate at each time point were calculated using the following formula to plot the release curve:
[0132] Cumulative release amount
[0133]
[0134] Where C n is the mass concentration of the sample at the nth time point, V is the volume of the release medium, C i is the concentration of the sample at time i, V0 is the volume of release medium taken each time, and W is the content of Cur in the dialysis bag.
[0135] 2.6 Biosafety
[0136] 2.6.1 Hemolysis test
[0137] Fresh whole blood samples from rats were collected and centrifuged at 2000rpm for 15 minutes to separate the blood components. The upper plasma was discarded, and the lower red blood cells were collected and diluted with normal saline to prepare a 2% red blood cell suspension. 500μL of the red blood cell suspension was mixed with Cur@BBO-BSP NLCG and CMG respectively, and incubated at 37°C for 0.5h. After the reaction was completed, it was centrifuged again at 2000rpm for 15 minutes, and the supernatant was separated. The absorbance value at the characteristic wavelength of 542nm was measured using an enzyme marker. Normal saline and distilled water were used as negative and positive controls, respectively, and the hemolysis rate was calculated according to the following formula:
[0138]
[0139] Where: OD SOD is the absorbance value of the sample solution at 542 nm; NC is the absorbance value of the negative control solution at 542 nm; OD PC is the absorbance value of the positive control solution at 542 nm.
[0140] 2.6.2 Cytotoxicity assay
[0141] L929 cells were cultured at 2×10 4 Cells were seeded at a density of 100 cells / well in a 96-well plate and incubated at 37°C and 5% CO2 for 24 hours. Untreated cells were used as blank controls, and untreated cells were used as blank controls. Cells were incubated with 12.5, 25, 50, 100, 200, and 250 μg / mL of Cur@BBO-BSP NLCG for 24 hours, respectively. 20 μL of MTT (5 mg / mL) reagent was added to each well and incubated for 4 hours. Subsequently, 100 μL of DMSO was added to each well. The absorbance at a wavelength of 490 nm was measured using a microplate reader, and the cell viability was calculated according to the following formula:
[0142]
[0143] Where: OD 样品组 OD is the absorbance value of the sample solution at 490 nm; 对照组 is the absorbance of the control solution at 490 nm.
[0144] 2.7 Cell scratch assay
[0145] The scratch healing assay using L929 cells was performed in 24-well plates as follows: L929 cells were seeded at a density of 2 × 104 cells per well and cultured overnight to form a complete cell layer. A vertical scratch was made on the cell surface using a sterile pipette tip, and the bottom of the well was then washed with pre-cooled PBS to remove detached cells. After discarding the PBS, the following treatments were added: (1) blank control group (DMEM medium); (2) blank BBO-BSP NLCG group; (3) potent curcumin solution group; (4) CMG group (positive control, Innomecd silicone gel scar dressing); and (5) Cur@BBO-BSP NLCG group. Cell images were captured using a Nikon Eclipse Ti microscope.
[0146] 2.8 Scarless Healing Study
[0147] 2.8.1 Establishment of rabbit ear wound model
[0148] Adult New Zealand white rabbits were secured to a surgical stent and the rabbit ear skin was anesthetized with 0.25% compound lidocaine ointment. A square incision was made in the rabbit ear's less vascularized tissue using a scalpel. The ear skin was then peeled off to create a square (0.9 cm × 0.9 cm) rabbit ear wound model.
[0149] 2.8.2 Study on wound healing and scar prevention in vivo
[0150] To evaluate the efficacy of Cur@BBO-BSP NLCG in promoting wound healing and preventing scarring, a silicone gel scar dressing (Zhejiang Longtai Medical Technology Co., Ltd.) was used as a positive control (CMG). Rabbit ear wound tissues were randomly divided into five groups: normal saline, BBO-BSP NLCG, free Cur solution, Cur@BBO-BSP NLCG, and CMG. Drugs were administered once daily starting on day 0 after wound model establishment. The size and color of the rabbit ear wounds, as well as the time it took for scabs to fall off naturally and for scar formation, were observed daily. Photographs were taken every five days for 30 days. Scar height was measured using a vernier caliper after scar formation. After 30 days of administration, scars from each group were collected and fixed with 4% paraformaldehyde solution. After fixation, the specimens were dehydrated using a graded ethanol series, clarified in xylene, and embedded in paraffin. Sections (4 μm) were obtained using a microtome (Leica RM 2016) and stained with Hematoxylin and Erythrocyte Embryo (H&E), Masson's trichrome, and Sirius Red. Immunohistochemistry was performed to detect the expression of CD31, VEGF, TNF-α, IL-6, and TGF-β1. Stained tissue sections were observed by light microscopy, and the staining images were semiquantitatively analyzed using ImageJ.
[0151] 3. Experimental results
[0152] 3.1BBO-BSP NLC formulation optimization
[0153] 3.1.1 Selection of liquid lipid ratio
[0154] High-quality BBO-BSP NLC should have good fluidity and stability. This study used particle size and stability as indicators to determine the proportion of Ai Na sesame oil. The results are as follows Figure 1 As shown in the results, when the BBO concentration varied from 0.5% to 5%, the particle size of the NLC ranged from approximately 170 to 240 nm, and the PDI values were all less than 0.24. After stabilization at room temperature, the BBO-BSP NLC samples with BBO contents of 0.5% and 1% were the most stable, while the remaining samples exhibited varying degrees of stratification and turbidity. Considering BBO's antioxidant and anti-inflammatory effects, a BBO content of 1% was selected.
[0155] 3.1.2 Selection of emulsifier ratio
[0156] In this study, the ratio of poloxamer 188 to Bletilla striata polysaccharide was optimized based on particle size and stability. Figure 2 The results show that the particle size and PDI were both smaller when the poloxamer 188:BSP ratio was 2:1 and 1:2. Observation at room temperature revealed that a 1:2 ratio of poloxamer 188 to Bletilla striata polysaccharide exhibited the best stability, while all other ratios resulted in turbidity and stratification. Taking into account particle size, PDI, and stability, a 1:2 ratio of poloxamer 188 to BSP was selected.
[0157] 3.1.3 Selection of emulsifier ratio
[0158] Egg yolk lecithin, as a natural amphiphilic phospholipid, has the dual functions of liposome structure skeleton and surfactant. Its amphiphilic properties can stabilize the morphology of nanolipid carriers (NLC) and mediate drug encapsulation and delivery. Figure 3 As shown, the BBO-BSP NLC with a 3% egg yolk lecithin content exhibited the largest particle size. At 4% and 5% egg yolk lecithin content, both the particle size and polydispersity index (PDI) were smaller. After one week of storage at room temperature, all BBO-BSP NLCs except the 4% egg yolk lecithin content exhibited varying degrees of turbidity. Based on the particle size, PDI, and stability results, the optimal egg yolk lecithin content was determined to be 4%.
[0159] 3.2 Preparation of CUR@BBO-BSP NLC and determination of encapsulation efficiency and drug loading
[0160] To determine the optimal loading concentration of CUR in BBO-BSP NLC, CUR@BBO-BSP NLCs at concentrations of 0.5 mg / mL, 1 mg / mL, 2 mg / mL, and 3 mg / mL were prepared using the optimal ratio determined in "2.1 Preparation of BBO-BSP NLC." Experimental results showed that CUR@BBO-BSP NLC exhibited good stability when the CUR concentration was ≤2 mg / mL. However, when the CUR concentration reached 3 mg / mL, particulate matter and precipitation appeared in the sample. Therefore, the optimal loading concentration of curcumin was determined to be 2 mg / mL.
[0161] The content of Cur was determined by dialysis method, and a standard curve was established with curcumin concentration c as the horizontal axis and absorbance A as the vertical axis. The results are shown in Figure 2. Figure 4 As shown, the linear regression equation is A=0.1642c+0.055 (r=0.9993), indicating that the method is linear in the curcumin loading concentration range of 1.69-6.20 μg / mL.
[0162] The optimized CUR@BBO-BSP NLC formulation is as follows: a 1:2 mass ratio of poloxamer 188 to Bletilla striata polysaccharide, 1% Artemisia selengensis oil, 4% egg yolk lecithin, 2 mg / mL curcumin, and 0.5% glyceryl monostearate. Using this optimal formulation, the resulting CUR@BBO-BSP NLC exhibited an average particle size of (172.6 ± 1.0) nm, a PDI of 0.106 ± 0.037, an EE (%) of 89.52 ± 2.28%, and a LE (%) of 4.73 ± 0.08%.
[0163] 3.3 Preparation of gel matrix
[0164] The comprehensive scoring results of the gel matrix prepared at different ratios of Carbapenem polysaccharide, Bohm 940 and glycerol are as follows: Figure 5-Figure 7 According to the comprehensive scoring results, the optimal formula of the gel matrix was finally determined to be: 1% carbomer 940, 4% glycerol, and 7% Bletilla striata polysaccharide.
[0165] 3.4 Preparation of CUR@BBO-BSP NLCG
[0166] After the gel matrix was prepared according to the optimal ratio, it was mixed with the CUR@BBO-BSP NLC prepared according to the optimal ratio in different proportions to obtain the comprehensive scores of the CUR@BBO-BSP NLCG samples. Figure 8 The results show that the optimal ratio of gel matrix to CUR@BBO-BSP NLC is 1:1.
[0167] 3.5 In vitro release experiment
[0168] Curcumin release curve Figure 9 As shown in the results, the release curve of free curcumin shows that its release rate is fast, with a burst release and a release rate of 67.92%. However, the release rates of CUR@BBO-BSP NLC and CUR@BBO-BSP NLCG in PBS buffer with pH 7.35 containing 2% Tween-80 at (37±5)℃ are slower than that of free curcumin. The sustained release time reaches 264h, and the release rates are 35.52% and 30.12%, respectively. This shows that both CUR@BBO-BSP NLC and CUR@BBO-BSP NLCG have a certain sustained release effect, and CUR@BBO-BSP NLCG shows a stronger sustained release effect in the experiment.
[0169] 3.6 Biosafety
[0170] Good safety and biocompatibility are important prerequisites for the clinical application of wound gel dressings. The safety and biocompatibility of Cur@BBO-BSP NLCG were comprehensively evaluated through blood compatibility and cytotoxicity tests.
[0171] Generally speaking, the lower the hemolysis rate, the better the blood compatibility. Figure 10 As shown in the figure, the hemolysis rates of Cur@BBO-BSP NLCG and CMG were similar, both below 2%, significantly lower than the 5% safety threshold specified in the National Biocompatibility Assessment Standard (GB / T16886.4-2022). This indicates that Cur@BBO-BSP NLCG has excellent hemocompatibility as a wound healing dressing.
[0172] The results of cell viability assay were as follows Figure 11 As shown in the Figure 3, after incubation with different concentrations of Cur@BBO-BSP NLCG for 24 h, the viability of L929 cells was close to or higher than 100%, indicating that Cur@BBO-BSP NLCG had good cell compatibility within the concentration range of 12.5-250 μg / mL.
[0173] 3.7 Cell scratch assay
[0174] The effect of Cur@BBO-BSP NLCG on L929 cell migration was evaluated by cell scratch assay. Representative images of L929 cell migration (red dashed line marks the scratch edge) are shown in Figure 3. Figure 12 As shown in Figure 2, the scratch closure rate is as follows: Figure 13 As shown, free curcumin BBO-BSP NLCG significantly promoted cell migration, which may be related to the intrinsic pro-migratory activity of BBO and BSP. Curcumin solution without any other ingredients also showed some pro-migratory effect, consistent with the results reported in the literature. Interestingly, Cur@BBO-BSP NLCG displayed the strongest pro-migratory effect in L929 cells. After 24 hours of co-culture, its wound closure rate was 76.32±0.32%, significantly superior to the 64.05±0.37% of the CMG group, the 55.04±1.87% of the blank vector BBO-BSP NLCG group, and the 59.12±0.30% of the free curcumin solution group.
[0175] 3.8 Study on wound healing and scar prevention in vivo
[0176] A rabbit ear wound model was constructed to investigate the effects of Cur@BBO-BSP NLCG on wound healing and scar prevention. Figure 14As shown (in the figure: A is a schematic diagram of the experimental design for scarless wound healing of rabbit ears; B is a picture of the rabbit ear wounds in each treatment group at different time points; C is the time of scar formation in each group; D is the scar height in each group, n=3).
[0177] like Figure 14 As shown in Figure B, on the first day of administration, granulation tissue began to form to varying degrees on the wound surfaces of all groups. By the fifth day, the epithelium surrounding the wound surface migrated toward the center and formed a scab, significantly reducing the wound area. The scabs in the saline group were scattered, while those in the BBO-BSP NLCG, Cur solution, and Cur@BBO-BSP NLCG groups formed complete scabs, with the Cur@BBO-BSP NLCG group showing the most significant wound shrinkage rate. The scabs in the CMG group showed signs of a purulent, whitish, inflammatory reaction. By the 15th day of administration, the scabs in the saline, BBO-BSP NLCG, and Cur@BBO-BSP NLCG groups had completely shed, while those in the free Cur solution and CMG groups had not yet completely shed. Hypertrophic scars had formed in the saline group, while the wound surface in the Cur@BBO-BSP NLCG group was relatively smooth, with no obvious scarring. On the 20th day of administration, scars appeared in all groups except the Cur@BBO-BSP NLCG group. These scars were red or light red, with a central area that began to rise above the healed wound surface and felt hard to the touch. In contrast, the Cur@BBO-BSP NLCG group healed better, with no obvious scarring. On the 30th day of administration, hypertrophic scars were largest in the saline and BBO-BSPNLCG groups, while those in the aqueous drug solution and positive drug dressing groups were smaller. In the Cur@BBO-BSP NLCG group, no scarring was observed on the wound surface, and a small amount of hair had grown, demonstrating a good scar-free healing effect.
[0178] like Figure 14 As shown in C, 15 days after surgery, a "hillock"-like raised scar appeared on the wound surface of the saline group. The initial scar formation time was recorded, and the scar height was measured every other day. The average initial scar formation time of each group was as follows. Figure 14As shown in Figure D, the wound healing time for the saline group was 15.00 days, the BBO-BSP NLC group was (16±2) days, the drug solution group was 16 days, and the positive drug excipient group was 18 days. However, no scars formed within 30 days of treatment with Cur@BBO-BSP NLCG. The final scar height was approximately 2.4 mm in the saline group, 0.7 mm in the BBO-BSP NLC group, and 0.9 mm in the drug solution group, indicating that both the BBO-BSP NLC group and the drug solution had a certain inhibitory effect on scar formation. The wounds in the Cur@BBO-BSP NLCG group showed the fastest healing rate and no scar tissue formed after healing, demonstrating a significantly better therapeutic effect than the positive drug excipient group (p < 0.01). These results suggest that Cur@BBO-BSP NLCG has potential application as a scarless healing dressing.
[0179] To further investigate the therapeutic effect of Cur@BBO-BSP NLCG on rabbit ear wounds, wound tissues were obtained 30 days after treatment for H&E staining, Masson staining, and Sirius red staining. The histological evaluation results were as follows: Figure 15 As shown in the figure: A is the H&E, Masson's trichrome and succinimidyl red staining of the wound 30 days after treatment; B is the scar elevation index SEI value of the wounds in different groups; C is the semi-quantitative analysis of collagen fiber density; D is the semi-quantitative analysis of succinimidyl red staining, n=3). The results of H&E staining show ( Figure 15 A) In the normal control group, skin tissue structure was intact, with uniform distribution of dermal fibroblasts at a moderate density and regular arrangement. In the saline group, due to the formation of HS, the epidermis and dermis showed significant thickening, with numerous nodular, disorderly arranged fibroblasts visible within the dermis, and their nuclei were prominently darkly stained. In contrast, the experimental groups treated with BBO-BSP NLC, free Cur solution, Cur@BBO-BSP NLCG, and CMG showed a decrease in fibroblast number and improvement in disordered arrangement. The Cur@BBO-BSP NLCG group showed the most significant effect, with cell density approaching that of normal tissue and more orderly arrangement, and histological appearance significantly superior to the other experimental groups. Quantitative SEI analysis showed that the Cur@BBO-BSP NLCG group had the lowest SEI value, which was not significantly different from the normal control group (SEI = 1), further confirming its inhibitory effect on scar hyperplasia. Masson staining results showed that the collagen fibers in the scar tissue of the saline group accumulated in clumps and were highly disordered; however, after Cur@BBO-BSP NLCG treatment, the density of collagen fibers decreased significantly, and the arrangement became more regular, close to that of normal skin tissue ( Figure 15A and 15C). Sirius red staining revealed that both the BBO-BSP NLCG group and the free Cur solution group reduced the type I / III collagen ratio to varying degrees. The Cur@BBO-BSP NLCG group had the lowest type I / III collagen ratio, which was not statistically different from the normal control group (p>0.5). These results suggest that Cur@BBO-BSP NLCG can promote scarless wound healing by regulating abnormal fibroblast proliferation, collagen synthesis and metabolism, and the type I / III collagen ratio.
[0180] Wound healing goes through four stages: hemostasis, inflammation, proliferation, and remodeling, which are closely related to biological processes such as inflammatory network activation, angiogenesis, and extracellular matrix synthesis. In this study, CD31, VEGF, TNF-α, IL-6, and TGF-β were selected as key markers for further research. Figure 16 As shown in the figure (A is the immunohistochemical staining of CD31, VEGF, TNF-α, IL-6 and TGF-β1; B is the semi-quantitative analysis of CD31; C is the semi-quantitative analysis of VEGF; D is the semi-quantitative analysis of TNF-α; E is the semi-quantitative analysis of IL-6; F is the semi-quantitative analysis of TGF-β1), the saline group showed significant positive staining for CD31 and VEGF. However, the positive staining for CD31 and VEGF in the BBO-BSP NLCG and free curcumin groups was significantly weakened. Interestingly, the positive staining in the Cur@BBO-BSP NLCG group was the lightest, and its quantitative analysis results ( Figure 16 B) Further confirmation showed that the expression rates of CD31 and VEGF in this group were the lowest, close to those in the normal group. There was no statistical difference in VEGF expression between the group and the normal group (P>0.05), suggesting that Cur@BBO-BSP NLCG can effectively reverse pathological vascular remodeling by precisely regulating the vascular endothelial growth factor network.
[0181] TNF-α and IL-6, as pro-inflammatory cytokines, play a key role in wound healing and the development of hypertrophic scars. Figure 16As shown in Figures 16A, 16D, and 16E, the saline group showed significantly higher TNF-α and IL-6 expression rates than the normal group (p<0.001 and p<0.0001, respectively), confirming a persistent inflammatory response. Free curcumin significantly reduced the expression of both factors (p<0.05). The BBO-BSP nanolipid carrier gel (NLCG) group exhibited a significant inhibitory effect on TNF-α (p<0.05), but the inhibition of IL-6 did not reach statistical significance. Notably, the Cur@BBO-BSP NLCG group had the lowest TNF-α and IL-6 expression rates, demonstrating superior anti-inflammatory efficacy compared to the positive control CMG group, demonstrating the potent anti-inflammatory activity of Cur@BBO-BSP NLCG.
[0182] TGF-β1 plays a core regulatory role in wound healing and hypertrophic scar formation, driving the fibrosis process through a multi-level signaling network. In the early stages of wound repair, TGF-β1 induces fibroblasts to differentiate into myofibroblasts by activating the TGF-β / Smad pathway, significantly upregulating the synthesis of extracellular matrix components such as type I collagen and fibronectin, and promoting collagen deposition and granulation tissue formation. However, in pathological scars, the abnormal and persistent activation of TGF-β1 leads to excessive proliferation of fibroblasts and imbalance in collagen metabolism, further exacerbating the abnormal proliferation of scar tissue. The expression level of TGF-β1 in hypertrophic scar tissue is significantly higher than that in normal skin. Figure 16 As shown in Figures A and 16F, the positive expression rate of TGF-β1 was low in the normal skin group, but significantly increased in the saline group (p < 0.001). TGF-β1 expression levels were significantly reduced after treatment with BBO-BSP NLCG and free curcumin. Notably, the TGF-β1 positive expression rate in the Cur@BBO-BSP NLCG group was the lowest, with no statistically significant difference compared to the normal group, indicating that Cur@BBO-BSP NLCG has excellent inhibitory activity against TGF-β1 expression.
[0183] The above results indicate that Cur@BBO-BSP NLCG exhibits synergistic therapeutic advantages in vascular remodeling, inflammation regulation, and TGF-β1 expression inhibition, and can effectively promote scarless wound healing.
[0184] Although the present invention has been described in detail above using general descriptions, specific embodiments, and experiments, it will be apparent to those skilled in the art that modifications and improvements may be made based on the present invention. Therefore, such modifications and improvements, which do not depart from the spirit of the present invention, are intended to be within the scope of protection claimed herein.
Claims
1. A compound Bletilla striata polysaccharide liposome gel, characterized in that: The compound Bletilla striata polysaccharide liposome gel is obtained by uniformly mixing a gel matrix and curcumin-loaded nanostructured liposomes; The gel matrix comprises the following components in percentage by mass: 1% to 11% of Bletilla striata polysaccharide, 0.3% to 1.3% of Carbomer 940, 1% to 7% of glycerol, and the solvent is water; The curcumin-loaded nanostructured liposomes comprise the following components in percentage by mass: an oil phase consisting of 0.5% glyceryl monostearate and 1% linalool oil; an aqueous phase consisting of 4% egg yolk lecithin, 1% co-emulsifier consisting of poloxamer 188 and bletilla striata polysaccharide, and distilled water; and curcumin at a concentration of 0.5 to 3 mg / mL in the nanostructured liposomes; wherein the mass ratio of poloxamer 188 to bletilla striata polysaccharide is 1:
2. The volume ratio of the gel matrix to the curcumin-loaded nanostructured liposome is 0.5-2:
1.
2. The compound Bletilla striata polysaccharide liposome gel according to claim 1, characterized in that: The gel matrix comprises the following components in percentage by mass: 5% to 9% of Bletilla striata polysaccharide, 0.9% to 1.3% of Carbomer 940, and 3% to 5% of glycerol, and the solvent is water.
3. The compound Bletilla striata polysaccharide liposome gel according to claim 2, characterized in that: The gel matrix comprises the following components in percentage by mass: 7% of Bletilla striata polysaccharide, 1.0% of Carbomer 940, and 4% of glycerol, and the solvent is water.
4. The compound Bletilla striata polysaccharide liposome gel according to claim 1, characterized in that: In the curcumin-loaded nanostructured liposomes, the concentration of curcumin in the nanostructured liposomes is 2 mg / mL.
5. The compound Bletilla striata polysaccharide liposome gel according to claim 1, characterized in that: The volume ratio of the gel matrix to the curcumin-loaded nanostructured liposome is 1-2:
1.
6. The compound Bletilla striata polysaccharide liposome gel according to claim 5, characterized in that: The volume ratio of the gel matrix to the curcumin-loaded nanostructured liposomes is 1:
1.
7. The method for preparing the compound Bletilla striata polysaccharide liposome gel according to any one of claims 1 to 6, characterized in that: The steps include: S1 Preparation of curcumin-loaded nanostructured liposomes: The preparation method is a heating melting-ultrasonic dispersion method, wherein curcumin is added to the oil phase, and the aqueous phase is slowly injected into the oil phase under magnetic stirring, continuously stirred, ultrasonically treated with a probe-type ultrasonic processor, cooled, and filtered to obtain the product; S2 Preparation of gel matrix: Take Carbomer 940 and soak it in distilled water to make it swell, add Bletilla striata polysaccharide solution, stir in a water bath, add glycerol, mix well, and adjust the pH value to 6.5-7 with triethylamine to obtain the product; S3 Preparation of compound Bletilla striata polysaccharide liposome gel: The curcumin-loaded nanostructured liposomes prepared in step S1 and the gel matrix prepared in step S2 are mixed evenly in proportion to obtain the product.
8. The method for preparing the compound Bletilla striata polysaccharide liposome gel according to claim 7, characterized in that: In step S1, the temperature of the magnetic stirring is 65°C; the continuous stirring time is 25 minutes; the ultrasonic power of the probe-type ultrasonic processor is 450W, and the ultrasonic time is 15 minutes; the cooling time is 5 minutes; and the filtration is specifically through a 0.22 μm microporous filter membrane, and the number of filtrations is 3 times.
9. The method for preparing the compound Bletilla striata polysaccharide liposome gel according to claim 7, characterized in that: The stirring in the water bath in step S2 is specifically: stirring in a 60° C. water bath for 6 hours.
10. Use of the compound Bletilla striata polysaccharide liposome gel according to any one of claims 1 to 6 in the preparation of a medicament for promoting scarless wound healing.
Citation Information
Patent Citations
Fatty acid nanostructure lipid carrier for improving bioavailability of curcumin
CN116139026A
